Keli Johnson

Senior Project Manager

Keli Johnson

Keli Johnson

Senior Project Manager

Keli Johnson has 9 years of experience leading Phase 1-3 clinical trials, as well as observational and mechanistic studies within the NIH/NIAID-funded Autoimmune Disease Clinical Trials program, Atopic Dermatitis Research Network, and the Consortium for Food Allergy Research Network, all part of the DAIT Statistical and Clinical Coordinating Center.

Currently, Ms. Johnson is a project leader for the Medical Countermeasures Clinical Studies Network (MCM-CSN) contract funded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical and Advanced Research Development Authority (BARDA). Ms. Johnson served as the project lead on the Phase 2 study to assess the efficacy of an H7 influenza vaccine with two adjuvants and currently serves as the project lead on the phase 1 three-way crossover study to assess the bioavailability and pharmacokinetics of atropine. Ms. Johnson will also serve as the project lead on the recently awarded second H7 study with BARDA.

Ms. Johnson has led a range of studies across therapeutic areas and indications, including dermatology (atopic dermatitis, eczema herpeticum),  autoimmune disorders (systemic lupus, systemic sclerosis, multiple sclerosis, rheumatoid arthritis, Sjögren’s syndrome), asthma, infectious disease (influenza, urinary tract infections), and food allergy. Ms. Johnson supported two NIAID funded studies in atopic dermatitis examining the safety and immunogenicity of an intradermal seasonal influenza vaccine. Ms. Johnson’s depth of experience across therapeutic areas gives her a strong understanding of clinical trial management across all stages of product development.

Ms. Johnson earned her Bachelor’s of Science in Biology from the University of North Carolina at Chapel Hill.